Lacidipina Mylan Pharma

Lacidipine, the active ingredient in Lacidipina Mylan Pharma, is a calcium channel blocker presented as an oral tablet for oral use. It treats hypertension in adult patients.

GNH USA supplies Lacidipina Mylan Pharma as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacidipine is used to manage high blood pressure, a key component of cardiovascular disease management.

- Hypertension: Lowers systolic and diastolic blood pressure, helping to reduce the risk of cardiovascular events.

Lacidipine may cause several adverse reactions, ranging from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness or light‑headedness, especially after standing. - Tachycardia: increased heart rate. - Nausea: occasional stomach upset.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure leading to fainting. - Myocardial infarction: rare occurrence of heart attack. - Hepatic dysfunction: abnormal liver enzyme elevations. - Allergic reactions: rash, pruritus, or urticaria. - Angioedema: swelling of face, lips, or throat. - Cardiovascular collapse: extremely rare life‑threatening event.

When prescribing lacidipine, clinicians should consider several safety measures. - Blood pressure monitoring: regularly assess to avoid excessive hypotension. - Hepatic impairment: use with caution; adjust dose if liver function is compromised. - Elderly patients: start at lower doses due to increased sensitivity. - Concomitant antihypertensives: monitor for additive blood‑pressure lowering effects. - Severe hypotension: contraindicated in patients with markedly low blood pressure. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Lacidipine can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase lacidipine plasma levels. - Grapefruit juice: can markedly raise drug concentrations. - Other potent antihypertensives: risk of additive hypotension.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce effectiveness. - Additional calcium‑channel blockers: monitor for cumulative effects. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive response. - Diuretics: watch for electrolyte disturbances. - Beta‑blockers: assess for excessive heart‑rate reduction.